ç§ãã¡ã®äœã«ãã£ã€ããããå容äœãRAGEã®è©±
å æ¥ãAGEs(çµæ«ç³åç£ç©)ã®å€ãé£äºã¯äœã«æªãã®ãããšãã話ãããŠããŠããµãšæ°ã«ãªã£ããã§ãããRAGEã£ãŠãçµå±ã©ããã£ãŠæããã°ãããã§ããããããšã
RAGEãšããã®ã¯ãAGEsãã¯ããS100ã¿ã³ãã¯è³ªãHMGB1ãªã©ãããããª"åä»è "ã«ãã£ã€ããŠã¯ççã®ã¹ã€ãããå ¥ããŠããŸãå容äœã§ã(Cross et al., 2024)ãããŒã«æ§å容äœ(TLR)ã®ããã«çžæãéžã°ãçµåãããããã°æåºŠã®é«ãããéçªã¿ãããªãã®ããã®éçªãèœã¡çãããããšãäžçäžã®ç ç©¶è ãããããªæåã詊ããŠããŸãã
仿¥ã¯ä»£è¡šçãª3ã€ã®æ€ç©ç±æ¥æåãšãæ€ç©ã«éããªãã¢ãããŒããåãããŠæ¯ã¹ãŠã¿ãããšæããŸããåããRAGE察çãã§ããçãå ŽæããŸãã§éããã§ããã
ãã®1:ç·è¶(EGCG) â éçªã®"圱æŠè "ãå¢ãã
ç·è¶ã®EGCGã1æ¥300ã900mgã2åç³å°¿ç ã®æ£è ããã«é£²ãã§ããã£ãèšåºè©ŠéšããããŸã(Huang et al., 2013)ãå°æ¹Ÿã®ç ç©¶ããŒã ã«ãããã®ã§ãçµæãè¡äžã®sRAGE(坿º¶æ§RAGE)ããã£ããå¢ããããã§ãã
sRAGEãšããã®ã¯ã现èèã«åãŸã£ãŠããRAGEæ¬äœãšã¯å¥ã«ãè¡æ¶²äžããµããµãæŒã£ãŠãã"ããšã"ã®ãããªååãAGEsãS100ã¿ã³ãã¯è³ªããã®ããšãã«å ã«æãŸã£ãŠãããã°ãæ¬ç©ã®RAGEãŸã§ãã©ãçãããççã®ã¹ã€ãããå ¥ããŸãããEGCGã¯ãADAM10ãšããé µçŽ ã䜿ã£ãŠRAGEã®äžéšãåãé¢ãããã®ããšããå¢ç£ãããããšããæ©åºã確èªãããŠããŸã(Huang et al., 2013)ã
âŠâŠãã ã§ãããããã§äžã€åŒã£ããã£ãããšããããŸãããç·è¶ã«ã¯ã«ãã§ã€ã³ãå ¥ã£ãŠãŸãããããããã¡ãããšé€ããŠãŸã?ããšã調ã¹ãŠã¿ããšããã®è«æã¯"EGCGãªãããªç·è¶ãšãã¹"ãšãã衚çŸã§ãè±ã«ãã§ã€ã³ãæèšããç ç©¶ã§ã¯ãªããããªãã§ã(Huang et al., 2013)ãã«ãã§ã€ã³ã«ãè æ©èœãã€ã³ã¹ãªã³æåæ§ãžã®ç¬èªã®äœçšããããŸãããã广ãEGCGã ãã®ææãªã®ãããã®ãããã¯ããå°ãæ éã«èŠãå¿ èŠãããããã§ããç§åŠã¯çã£ãŠãªããŒããšããããšã§ã
ãã®2:ã¬ã¹ãã©ãããŒã«+ãã¹ãã¬ãã³ â ããããéçªãæžããããããŠGlo1ãšããçžã®äžã®åæã¡
ãã¡ãã¯ç·è¶ãšã¯çºæ³ãéã§ããããšããå¢ãããã®ã§ã¯ãªããGlo1(ã°ãªãªããµã©ãŒãŒ1)ãšããé µçŽ ãå¢ãããŠãããããRAGEã«å±ããªã¬ã³ãã®éèªäœãæžããæ¹åã§ãã
Glo1ã¯ãAGEsã®äž»èŠãªåé§ç©è³ªã§ããã¡ãã«ã°ãªãªããµãŒã«(MG)ãè§£æ¯ããŠãããé µçŽ ã§ãäœå ã§çããMGã®9å²ä»¥äžã代è¬ããŠãããšèŠç©ããããŠããŸã(Rabbani, 2022)ãéäœéã»è¥æºã§ã€ã³ã¹ãªã³æµææ§ã®ãã29人ã察象ã«ããã¯ãã¹ãªãŒããŒè©Šéšã§ãã¬ã¹ãã©ãããŒã«ãšãã¹ãã¬ãã³(ææ©ç±æ¥ã®ãã©ããã€ã)ã®çµã¿åãã(tRES-HESP)ãGlo1ã®çºçŸã»æŽ»æ§ã27%åŒãäžããè¡äžã¡ãã«ã°ãªãªããµãŒã«ã37%ãäœå ã®ç³åã¿ã³ãã¯è³ªã14%æžãããããšãå ±åãããŠããŸã(Rabbani et al., 2016)ãç©ºè ¹æã»é£åŸã®è¡ç³å€ãæ¹åããããã§ã(Rabbani et al., 2016)ã
ç¶å ±ã§ã¯ããã®çµã¿åãããããå ç®çްèã»ç·ç¶èœçްèã»èçŽ°èæ ªã«ãããŠãNrf2çµè·¯ãä»ããŠGlo1é¢é£éºäŒå矀ãå¢ããããšã確èªãããŠãããGlucoRegulateãšããååã§ãµããªã¡ã³ãåããããŠããŸã(Rabbani et al., 2025)ã
ãã®3:ãã â éçªãšå®¢ãåŒãé¢ããçŽæ¥ãããã¯å
ããŠã3ã€ç®ã¯ããã§ãã
ããã®n-ãã¿ããŒã«æœåºç©ã«ã¯ãAGEsãšRAGEã®çµåãã®ãã®ããããã¯ããäœçšãããããšããä¹ ç米倧åŠã®ã°ã«ãŒããšã®å ±åç ç©¶ã§ç€ºãããŸãã(Ishibashi et al., 2017)ãããã®è¡ç®¡å ç®çްè(HUVEC)ã䜿ã£ãå®éšã§ã¯ãAGEsã«æããã现èã®ROSç£çãççæ§éºäŒåçºçŸ(RAGEã»ICAM-1ã»PAI-1)ãããã®æœåºç©ã«ãã£ãŠææã«æããããããšã確èªãããŠããŸã(Ishibashi et al., 2017)ã
ç·è¶ããããšããå¢ããããã¬ã¹ãã©ãããŒã«+ãã¹ãã¬ãã³ããGlo1ãå¢ãããŠããããéãæžãããã ãšãããšãããã¯ããã£ã€ãåã«åŒãé¢ããã¿ã€ãã3ã€ãšãåãRAGEãšããçãçã£ãŠããªãããçãæ¹ããŸã£ããéãã䞊ã¹ãŠã¿ããšãããããªããªãé¢çœããã§ããã
çªå€ç·š:Glo1ã¯æ€ç©æåã ãã®ãã®ãããªã
ãããŸã§æ€ç©ç±æ¥ã®è©±ãããŠããŸããããGlo1ãå¢ããæ¹æ³ã¯æ€ç©æåã«éã£ã話ã§ã¯ãããŸããã
éå(æé žçŽ ãã¬ãŒãã³ã°) ãããã£ããšããGlo1èªå°ã®ææ®µã§ããéªšæ Œçã¯å šèº«ã®ã€ã³ã¹ãªã³å¿çæ§ã°ã«ã³ãŒã¹åã蟌ã¿ã®8å²ä»¥äžãæ ãçµç¹ã§ãããã§ã®ãžã«ã«ããã«ã¹ãã¬ã¹(MGèç©)ãã€ã³ã¹ãªã³æµææ§ã2åç³å°¿ç ã®ç æ ã«é¢ããããšãç¥ãããŠããŸããããã®å¯ŸçãšããŠãæ é€è£å©é£åã«ããGlo1èªå°ããšäžŠãã§ãæé žçŽ éåãã¬ãŒãã³ã°ããææãªäººã§ã®æ²»çã³ã³ã»ãããšããŠæããããŠããŸã(Haus & Solomon, 2018)ãéåã奜ããªæ¹ã«ã¯æå ±ã§ããã
ã¡ããã«ãã³ ã¯ã¡ãã£ãšããããããŠãæèã«ãã£ãŠå¹æã®åããå€ãããŸãã2åç³å°¿ç +é žåèçŸæ£ã®æ£è ããã察象ã«ããç ç©¶ã§ã¯ãã¡ããã«ãã³æäžçŸ€ã§æ«æ¢¢è¡çްèã®Glo1掻æ§ãäžãããåè硬åç å€çµç¹ã§ãGlo1掻æ§(çºçŸéã§æ£èŠåããå€)ãææã«å¢å ããŠããŸãã(Vasaèªã®ç ç©¶, 2020幎代)ãäžæ¹ã§ãåç«è ºãã现è(PC3)ã䜿ã£ãå®éšã§ã¯ãã¡ããã«ãã³ã¯éã«Glo1çºçŸãçšéäŸåçã«æå¶ãããã现èã®æµžæœ€ã»è»¢ç§»èœã匱ããæ¹åã«åããŠããŸãã(Antognelli et al., 2018)ãåãè¬ã§ããè¡ç®¡ãå®ãããæèãšããã现èã匱ããããæèãšã§ã¯ãGlo1ããå¢ãããããæžããããããã®çããéã«ãªãããšããããã§ããããã¯åå話ããsRAGEã®ãéã®æå³ã¯æèäŸåããšãã話ãšãã©ããéãããã®ããããŸããã
ãŸãšãããš

ã©ããèšåºè©Šéšã®èŠæš¡ã¯ãŸã å°ãããæ€ç©æåã«ã€ããã®ã®ãææã ãã©åžåããã«ããããšããADMEã®å£ãæ±ããŠããŸããäžã€ã®æåã»äžã€ã®ææ®µã§å šéšè§£æ±ºããšããããã«ã¯ãããªããã§ãã
ãã ãããããŠæ©åºããšã«æŽçããŠã¿ããšãRAGE察çãšããã®ã¯äžæå²©ã§ã¯ãªããããã€ãã®å ¥ãå£ããããã ãªããšããã®ã宿ãšããŠããããŸããããšããéã蟌ããããããæ°ãæžãããçŽæ¥åŒãé¢ããäœãåãããŠé µçŽ ãåºäžããããå°æãé£åãããã«éåéŽã®äžã«ãŸã§ããããªç¥æµãç ã£ãŠãããšããããã¡ãã£ãšæå¿«ãããããŸãããã
åèæç®
Cross K, Vetter SW, Alam Y, Hasan MZ, Nath AD, Leclerc E. (2024) Role of the receptor for advanced glycation end products (RAGE) and its ligands in inflammatory responses. Biomolecules 14(12):1550. doi:10.3390/biom14121550
Huang SM, Chang YH, Chao YC, Lin JA, Wu CH, Lai CY, Chan KC, Tseng ST, Yen GC. (2013) EGCG-rich green tea extract stimulates sRAGE secretion to inhibit S100A12-RAGE axis through ADAM10-mediated ectodomain shedding of extracellular RAGE in type 2 diabetes. Mol Nutr Food Res 57(12):2264-2268. PMID: 23901023
Rabbani N, Xue M, Weickert MO, Thornalley PJ. (2016) Improved glycemic control and vascular function by a glyoxalase 1 inducer formulation in overweight and obese subjects: a randomised, placebo-controlled crossover trial. Diabetes Care(é¢é£è«æãPMID: 27207552)
Rabbani N. (2022) Methylglyoxal and glyoxalase 1 â a metabolic stress pathway. (ç·èª¬)
Rabbani N et al. (2025) Glyoxalase 1 Inducer, trans-Resveratrol and Hesperetin â Dietary Supplement with Multi-Modal Health Benefits. Antioxidants (PMC12382748)
Ishibashi Y, Matsui T, Isami F, Abe Y, Sakaguchi T, Higashimoto Y, Yamagishi S. (2017) N-butanol extracts of Morinda citrifolia suppress advanced glycation end products (AGE)-induced inflammatory reactions in endothelial cells through its anti-oxidative properties. BMC Complement Altern Med 17:137. doi:10.1186/s12906-017-1641-3
Haus JM, Solomon TPJ. (2018) Dicarbonyl stress and glyoxalase-1 in skeletal muscle: implications for insulin resistance and type 2 diabetes. (ç·èª¬ãPMC6139330)
åè硬åç å€ãšã¡ããã«ãã³ã»Glo1掻æ§ã«é¢ããç ç©¶(Vasaèªæ²èŒãæ£è 33å察象ã®ååãç ç©¶)
Antognelli C. et al. (2018) Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control, involving metformin-mediated Glo1æå¶ãšmiR-101ã®é¢äžãJ Cell Mol Med(PMC5908125)
